Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is an experimental small molecule inhibitor with the chemical formula C28H29F3N6 and a molecular weight of approximately 506.6 g/mol. It is not approved for clinical use and has no known brand names or marketed indications. The primary known mechanism of action is inhibition of mitogen‑activated protein kinase 14 (MAPK14, also known as p38 alpha), a serine/threonine kinase involved in inflammatory signaling pathways and cellular stress responses. The compound has been referenced in structural biology databases (e.g., PDB ligand "084") and cheminformatics resources but does not appear to have advanced into clinical trials or commercial development[3][6]. No developer or manufacturer information is available.
- Other names
- 4-[5-[2-(1-PHENYL-ETHYLAMINO)-PYRIMIDIN-4-YL]-1-METHYL-4-(3-TRIFLUOROMETHYLPHENYL)-1H-IMIDAZOL-2-YL]-PIPERIDINE4-{1-methyl-2-piperidin-4-yl–4-[3-(trifluoromethyl)phenyl]–1H-imidazol–5–yl}-N–[(1S)–1–phenylethyl]pyrimidin–2–amine
02
Targets
MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine.